China Fibrodysplasia Ossificans Progressiva (FOP) Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal genetic disease that results in abnormal bone formation (heterotopic ossification) in areas of skeletal muscles and connective tissues. FOP occurs progressively during lifetime, and most patients die at an average age of 40 years, The global prevalence of FOP is estimated approximately 1 in 200,000 population. It is estimated that China has approximately 700 FOP patients, the largest number in the world. China, which accounts for about 10.8% of registered patients.
China is a growing market for fibrodysplasia ossificans progressiva (FOP) disease due to increase in global prevalence rate (1 in 200,000 population), increase in awareness of disease. Other factors such as genetic mutations and high demand for new treatment leads to growth of fibrodysplasia ossificans progressiva (FOP) drugs market.
There are some restraining factors for the growth of fibrodysplasia ossificans progressiva (FOP) therapeutics market in China such as complex diagnosis procedures and high cost of treatment.